Table 2.
Systematic review: Patient characteristics (n=70).
| Characteristic | Study cohort (n=70) | APR group (n=34) | CRT+APR group (n=19) | APR+CRT group (n=17) |
|---|---|---|---|---|
| Age (y) | ||||
| Median | 56.0 | 58.5 | 62.0 | 47.0 |
| Mean ± SD | 56.6 ± 12.1 | 57.5 ± 12.1 | 60.4 ± 11.1 | 50.5 ± 11.5 |
| Range | 32.0-80.0 | 35.0-79.0 | 34.0-80.0 | 32.0-80.0 |
| Gender | ||||
| Female | 11 (16) | 5 (15) | 4 (21) | 2 (12) |
| Male | 59 (84) | 29 (85) | 15 (79) | 15 (88) |
| Fistula duration (y) | ||||
| <10 | 28 (40) | 13 (38) | 8 (42) | 7 (41) |
| ≥10 | 31 (44) | 18 (53) | 6 (32) | 7 (41) |
| ND | 11 (16) | 3 (9) | 5 (26) | 3 (18) |
| Crohn’s disease | ||||
| No | 54 (77) | 28 (82) | 16 (84) | 10 (59) |
| Yes | 16 (23) | 6 (18) | 3 (16) | 7 (41) |
| Histological type | ||||
| AD | 18 (26) | 13 (38) | 3 (16) | 2 (12) |
| MA | 52 (74) | 21 (62) | 16 (84) | 15 (88) |
| T stage | ||||
| T2 | 9 (13) | 4 (12) | 1 (5) | 4 (23) |
| T3 | 29 (41) | 8 (23) | 11 (58) | 10 (59) |
| T4 | 9 (13) | 4 (12) | 2 (11) | 3 (18) |
| ND | 23 (33) | 18 (53) | 5 (26) | 0 (0) |
| N stage | ||||
| N0 | 46 (66) | 27 (79) | 8 (42) | 11 (65) |
| N1/2/3 | 13 (18) | 1 (3) | 6 (32) | 6 (35) |
| ND | 11 (16) | 6 (18) | 5 (26) | 0 (0) |
| M stage | ||||
| M0 | 49 (70) | 21 (62) | 11 (58) | 17 (100) |
| M1 | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| ND | 21 (30) | 13 (38) | 8 (42) | 0 (0) |
| Follow up time (months) | 24 (24) | 25 (35) | 24 (16) | 16 (22) |
APR, abdominoperineal resection; CRT, chemoradiotherapy; SD, standard deviation; AD, adenocarcinoma; MA, mucinous adenocarcinoma; ND, not defined.
All values expressed as n (%) or median (IQR), unless otherwise noted.